Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment

Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment

Cemiplimab is a highly potent, hinge-stabilized human IgG4 monoclonal antibody (mAb) targeting programmed cell death 1 (PD-1) receptor approved for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (SCC) who are not candidates for curative surgery or curative radiation....

Full description

Bibliographic Details
Main Authors:	Lorenzo Antonuzzo, Sara Fancelli, Maria Cristina Petrella, Elisabetta Gambale, Enrico Caliman, Laura Doni, Serena Pillozzi
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-01-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/10/1/e003540.full

Similar Items

Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study
by: Agnese Paderi, et al.
Published: (2021-08-01)

Unconventional strategy could be the future: From target to KRAS broad range treatment
by: Sara Fancelli, et al.
Published: (2024-05-01)

IMGT/mAb-KG: the knowledge graph for therapeutic monoclonal antibodies
by: Gaoussou Sanou, et al.
Published: (2024-06-01)

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
by: Daniele Lavacchi, et al.
Published: (2022-11-01)

Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB
by: Taciana Manso, et al.
Published: (2023-05-01)

The mAB 13A4 monoclonal antibody to the mouse PROM1 protein recognizes a structural epitope.
by: Fatimah Matalkah, et al.
Published: (2022-01-01)

The mAB 13A4 monoclonal antibody to the mouse PROM1 protein recognizes a structural epitope
by: Fatimah Matalkah, et al.
Published: (2022-01-01)

Concentration Effects in the Interaction of Monoclonal Antibodies (mAbs) with their Immediate Environment Characterized by EPR Spectroscopy
by: Haleh H. Haeri, et al.
Published: (2019-07-01)

1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
by: Kyriakos Papadopoulos, et al.
Published: (2023-11-01)

Impact of natremia on metastatic non small cell lung cancer patients receiving immune checkpoint inhibitors
by: Martina Catalano, et al.
Published: (2024-11-01)

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis
by: Joe Q. Wei, et al.
Published: (2023-06-01)

The Different Colors of mAbs in Solution
by: Alexandre Ambrogelly
Published: (2021-05-01)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.
by: Marnie L Fusco, et al.
Published: (2015-10-01)

Treatment of Marmoset Intracerebral Hemorrhage with Humanized Anti-HMGB1 mAb
by: Dengli Wang, et al.
Published: (2022-09-01)

Dual “mAb” HER family blockade in head and neck cancer human cell lines combined with photon therapy
by: Jean-Baptiste Guy, et al.
Published: (2017-09-01)

Novel identification of mAbs by Raman spectroscopy
by: Maoqin Duan, et al.
Published: (2024-12-01)

Developments and Challenges for mAb-Based Therapeutics
by: Satoshi Ohtake, et al.
Published: (2013-08-01)

Delving into Molecular Pathways: Analyzing the Mechanisms of Action of Monoclonal Antibodies Integrated in IMGT/mAb-DB for Myasthenia Gravis
by: Rebecca Golfinopoulou, et al.
Published: (2023-11-01)

Retrospective Analysis of Vaccinated and Unvaccinated COVID-19 Patients Treated with Monoclonal Antibodies (mAb) and Their Emergent Needs (RAVEN)
by: Gordana Simeunovic, et al.
Published: (2023-03-01)

Bigdata analytics identifies metabolic inhibitors and promoters for productivity improvement and optimization of monoclonal antibody (mAb) production process
by: Caitlin Morris, et al.
Published: (2020-06-01)

KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population
by: Sara Fancelli, et al.
Published: (2022-11-01)

Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study
by: Alessia Bellotti, et al.
Published: (2025-01-01)

Neutralizing Monoclonal Antibody, mAb 10D8, Is an Effective Detoxicant against Abrin-a Both In Vitro and In Vivo
by: Zhi Li, et al.
Published: (2022-02-01)

Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
by: Jingzhe Zhang, et al.
Published: (2019-08-01)

Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients
by: Elisa Giommoni, et al.
Published: (2021-08-01)

Flow cytometric assessment of the reactivity of a panel of monoclonal antibodies (mAb) against two populations of human dendritic cells (DC)
by: Nunez Rafael, et al.
Published: (2001-07-01)

HUMANIZED MONOCLONAL-ANTIBODY (MAB) THERAPY FOR WEGENERS GRANULOMATOSIS (WG)
by: Lockwood, C, et al.
Published: (1995)

Diet effects on colonic health influence the efficacy of Bin1 mAb immunotherapy for ulcerative colitis
by: Sunil Thomas, et al.
Published: (2023-07-01)

Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer
by: Qiao Li, Takekazu Iuchi, Maria N. Jure-Kunkel, Alfred E. Chang
Published: (2007-01-01)

Costimulation blockade by combining CTLA4Ig with anti-CD40L mAb markedly inhibits the inflammatory response of experimental autoimmune myocarditis
by: Qing-Quan Chen, et al.
Published: (2017-04-01)

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
by: Josée Golay, et al.
Published: (2020-10-01)

Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer
by: Xiuying Li, et al.
Published: (2023-03-01)

Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma
by: Chen Y, et al.
Published: (2022-09-01)

Inhibitory Effect of Human Anti-CA I Autoantibodies and Development of Monoclonal Antibody mAb 2B8 Targeting Carbonic Anhydrase I
by: Petra Chalova, et al.
Published: (2024-01-01)

Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)
by: Elizabeth Seng, et al.
Published: (2024-09-01)

Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
by: Michaela Liedtke, et al.
Published: (2012-01-01)

Trends involving monoclonal antibody (mAb) research and commercialization: A scientometric analysis of IMS Lifecycle R&D Focus Database (1980–2016)
by: Yunfeng Lai, et al.
Published: (2018-04-01)

A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients
by: Monteiro Renato C, et al.
Published: (2011-06-01)

Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.
by: Vincent Boudousq, et al.
Published: (2013-01-01)

A phase I study of Tc-99m-h-R3 monoclonal antibody (DiaCIM (R)), a humanized monoclonal antibody (mAB) for imaging EGFR-positive malignancies.
by: Reilly, R, et al.
Published: (2002)